David B. Page

David B. Page

Auto-generated profile, based on publicly available information

David B. Page

Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2014 in Annual Review of Medicine
Verified
Journal Article
Closed access
DPDavid B. Page
David B. Page
MPMichael Postow
Michael Postow
MCMargaret K. Callahan
Margaret K. Callahan
JAJames P. Allison
James P. Allison
JWJedd D. Wolchok
Jedd D. Wolchok
Ipilimumab is the prototypical immunomodulatory antibody, approved by the FDA in 2011 for advanced melanoma on the basis of survival benefit. Since that time, we have made significant strides in optimizing this therapy: we have characterized the spectrum of immune-related adverse events and learned how to mitigate them with treatment algorithms, discovered potential biomarkers of activity, and identified the potential synergy between checkpoint modulation and other therapeutic modalities. Recent phase I trials have established the efficacy and safety of next-generation checkpoint agents, including PD-1 and PD-L1 inhibitors, across multiple tumor types. Much work lies ahead in developing these next-generation checkpoint agents, testing them in combination, and determining how to integrate them into the treatment paradigms of various tumor types.


10 August 2013 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
DPDavid B. Page
David B. Page
MPMichael Postow
Michael Postow
MCMargaret K. Callahan
Margaret K. Callahan
JWJedd D. Wolchok
Jedd D. Wolchok

16 June 2015 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
DPDavid B. Page
David B. Page
ABAriel Bulua Bourla
Ariel Bulua Bourla
ADAnthony Daniyan
Anthony Daniyan
JNJarushka Naidoo
Jarushka Naidoo
ESEric Smith
Eric Smith
MCMargaret K. Callahan
Margaret K. Callahan
The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old, have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the fundamentals of tumor immunology are translating into clinical success, with recent US Food and Drug Administration approval of several immunotherapies that improve clinical outcomes across prostate cancer, metastatic melanoma, non-small cell lung cancer and lymphocytic leukemia. In tandem with these clinical successes, new technologies such as high-throughput DNA/RNA sequencing, genetic engineering, and streamlined ex vivo cell culturing have paved the way for the next generation of immunotherapies and provided new tools for investigating potential biomarkers of response to existing therapies. During the November 2014 Annual Meeting of the Society of the Immunotherapy of Cancer, leaders in tumor immunology and cancer immunotherapy convened at the second annual SITC Primer to review both current knowledge and future directions in the field. Here, we will review the key discussions across a variety of topics, including innate immunity, adaptive immunity, dendritic cells, adoptive T cell therapy, anti-tumor antibodies, cancer vaccines, immune checkpoint blockade, challenges to immunotherapy, monitoring immune responses, and immunotherapy clinical trial design.

1 November 2014
Verified
Journal Article
Closed access
SFSamuel A Funt
Samuel A Funt
DPDavid B Page
David B Page
JWJedd D Wolchok
Jedd D Wolchok
MPMichael Postow
Michael Postow

2 June 2015 in npj Breast Cancer
Verified
Journal Article
Open access
DPDavid B Page
David B Page
JNJarushka Naidoo
Jarushka Naidoo
HMHeather L McArthur
Heather L McArthur
Npj Breast Cancer, Published online: 2 June 2015; | doi:10.1038/npjbcancer.2015.1